Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

5.1%

3 terminated/withdrawn out of 59 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

10%

6 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed trials have results

Key Signals

26 recruiting

Enrollment Performance

Analytics

Phase 1
37(62.7%)
Phase 2
16(27.1%)
Phase 3
6(10.2%)
59Total
Phase 1(37)
Phase 2(16)
Phase 3(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (59)

Showing 20 of 59 trials
NCT05681819Phase 1Completed

A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Role: lead

NCT06474455Phase 1Recruiting

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Role: lead

NCT05549947Phase 2Completed

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Role: lead

NCT07490613Phase 1Not Yet Recruiting

A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

Role: lead

NCT06877247Phase 1Completed

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

Role: lead

NCT06012812Phase 2Completed

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Role: lead

NCT07073534Phase 1Recruiting

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Role: lead

NCT07350928Phase 3Recruiting

Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status

Role: collaborator

NCT07296341Phase 1Recruiting

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Role: lead

NCT07268040Phase 2Recruiting

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Role: lead

NCT07301333Phase 1Recruiting

A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects

Role: lead

NCT06350006Phase 1Recruiting

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Role: lead

NCT06512051Phase 1Recruiting

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Role: lead

NCT07229586Phase 1Recruiting

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

Role: lead

NCT06434961Phase 3Completed

The Trial of SHR6508 in Secondary Hyperparathyroidism

Role: lead

NCT07229729Phase 2Recruiting

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Role: lead

NCT05203705Phase 2Terminated

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

Role: lead

NCT05836948Phase 1Recruiting

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Role: lead

NCT05740202Phase 1Active Not Recruiting

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

Role: lead

NCT05162469Phase 1Completed

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Role: lead